DOI QR코드

DOI QR Code

Survival in clinical stage I endometrial cancer with single vs. multiple positive pelvic nodes: results of a multi-institutional Italian study

  • Uccella, Stefano (Department of Woman and Child Health, Fondazione Policlinico Gemelli, I.R.C.C.S., Catholic University of the Sacred Heart) ;
  • Falcone, Francesca (Department of Gynecologic Oncology Surgery, Istituto Nazionale Tumori "Fondazione G. Pascale", I.R.C.C.S.) ;
  • Greggi, Stefano (Department of Gynecologic Oncology Surgery, Istituto Nazionale Tumori "Fondazione G. Pascale", I.R.C.C.S.) ;
  • Fanfani, Francesco (Department of Medicine and Ageing Sciences, G. D'Annunzio University of Chieti-Pescara) ;
  • De Iaco, Pierandrea (Department of General Surgery and Gynecologic Oncology Unit, Sant'Orsola Hospital) ;
  • Corrado, Giacomo (Department of Woman and Child Health, Fondazione Policlinico Gemelli, I.R.C.C.S., Catholic University of the Sacred Heart) ;
  • Ceccaroni, Marcello (Department of Obstetrics and Gynecology, Gynecologic Oncology and Minimally-Invasive Pelvic Surgery, International School of Surgical Anatomy, Sacred Heart Hospital) ;
  • Mandato, Vincenzo Dario (Unit of Obstetrics and Gynecology, Azienda USL-I.R.C.C.S. di Reggio Emilia) ;
  • Bogliolo, Stefano (Unit of Gynecologic Cancer Surgery European Institute of Oncology) ;
  • Casarin, Jvan (Department of Obstetrics and Gynecology, University of Insubria) ;
  • Monterossi, Giorgia (Department of Woman and Child Health, Fondazione Policlinico Gemelli, I.R.C.C.S., Catholic University of the Sacred Heart) ;
  • Pinelli, Ciro (Department of Obstetrics and Gynecology, University of Insubria) ;
  • Mangili, Giorgia (Department of Gynecology and Obstetrics, I.R.C.C.S. San Raffaele Hospital) ;
  • Cormio, Gennaro (Gynecologic Oncology Unit, I.R.C.C.S., National Cancer Institute "Giovanni Paolo II") ;
  • Roviglione, Giovanni (Department of Obstetrics and Gynecology, Gynecologic Oncology and Minimally-Invasive Pelvic Surgery, International School of Surgical Anatomy, Sacred Heart Hospital) ;
  • Bergamini, Alice (Department of Gynecology and Obstetrics, I.R.C.C.S. San Raffaele Hospital) ;
  • Pesci, Anna (Department of Pathology, Sacred Heart Hospital) ;
  • Frigerio, Luigi (Department of Obstetrics and Gynecology, Ospedale Papa Giovanni XXIII) ;
  • Uccella, Silvia (Department of Medicine and Surgery, Unit of Pathology, University of Insubria) ;
  • Vizza, Enrico (Department of Oncological Surgery, Gynecologic Oncologic Unit, "Regina Elena" National Cancer Institute) ;
  • Scambia, Giovanni (Department of Woman and Child Health, Fondazione Policlinico Gemelli, I.R.C.C.S., Catholic University of the Sacred Heart) ;
  • Ghezzi, Fabio (Department of Obstetrics and Gynecology, University of Insubria)
  • Received : 2018.05.24
  • Accepted : 2018.08.24
  • Published : 2018.11.10

Abstract

Objective: To investigate survival outcomes in endometrioid endometrial cancer (EEC) patients with single vs. multiple positive pelvic lymph nodes. Methods: We performed a retrospective evaluation of all consecutive patients with histologically proven International Federation of Gynecology and Obstetrics (FIGO) stage IIIC1 EEC who underwent primary surgical treatment between 2004 and 2014 at seven Italian gynecologic oncology referral centers. Patients with pre- or intra-operative evidence of extra-uterine disease (including the presence of bulky nodes) and patients with stage IIIC2 disease were excluded, in order to obtain a homogeneous population. Results: Overall 140 patients met the inclusion criteria. The presence of >1 metastatic pelvic node was significantly associated with an increased risk of recurrence and mortality, compared to only 1 metastatic node, at both univariate (recurrence: hazard ratio [HR]=2.19; 95% confidence interval [CI]=1.2-3.99; p=0.01; mortality: HR=2.8; 95% CI=1.24-6.29; p=0.01) and multivariable analysis (recurrence: HR=1.91; 95% CI=1.02-3.56; p=0.04; mortality: HR=2.62; 95% CI=1.13-6.05; p=0.02) and it was the only independent predictor of prognosis in this subset of patients. Disease-free survival (DFS) and disease-specific survival (DSS) were significantly longer in patients with only 1 metastatic node compared to those with more than 1 metastatic node (p=0.008 and 0.009, respectively). Conclusion: The presence of multiple metastatic nodes in stage IIIC1 EEC represents an independent predictor of worse survival, compared to only one positive node. Our data suggest that EEC patients may be categorized according to the number of positive nodes.

Keywords

References

  1. Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC. Current issues in the management of endometrial cancer. Mayo Clin Proc 2008;83:97-112. https://doi.org/10.4065/83.1.97
  2. Mariani A, Webb MJ, Keeney GL, Aletti G, Podratz KC. Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol 2002;84:437-42. https://doi.org/10.1006/gyno.2001.6550
  3. ASTEC study group, Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009;373:125-36. https://doi.org/10.1016/S0140-6736(08)61766-3
  4. Benedetti Panici P, Basile S, Maneschi F, Alberto Lissoni A, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008;100:1707-16. https://doi.org/10.1093/jnci/djn397
  5. Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010;375:1165-72. https://doi.org/10.1016/S0140-6736(09)62002-X
  6. Mariani A, Dowdy SC, Cliby WA, Haddock MG, Keeney GL, Lesnick TG, et al. Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecol Oncol 2006;101:200-8. https://doi.org/10.1016/j.ygyno.2006.01.032
  7. Uccella S, Podratz KC, Aletti GD, Mariani A. Lymphadenectomy in endometrial cancer. Lancet 2009;373:1170.
  8. Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2016;27:16-41. https://doi.org/10.1093/annonc/mdv484
  9. National Comprehensive Cancer Network. NCCN Clinical practice guidelines in oncology. Uterine neoplasms, Version 1.2018 [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; [cited 2017 Oct 17]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.
  10. Ballester M, Dubernard G, Lecuru F, Heitz D, Mathevet P, Marret H, et al. Detection rate and diagnostic accuracy of sentinel-node biopsy in early stage endometrial cancer: a prospective multicentre study (SENTI-ENDO). Lancet Oncol 2011;12:469-76. https://doi.org/10.1016/S1470-2045(11)70070-5
  11. Zahl Eriksson AG, Ducie J, Ali N, McGree ME, Weaver AL, Bogani G, et al. Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. Gynecol Oncol 2016;140:394-9. https://doi.org/10.1016/j.ygyno.2015.12.028
  12. Chan JK, Kapp DS, Cheung MK, Osann K, Shin JY, Cohn D, et al. The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. Br J Cancer 2007;97:605-11. https://doi.org/10.1038/sj.bjc.6603898
  13. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95 Suppl 1:S105-43. https://doi.org/10.1016/S0020-7292(06)60031-3
  14. American Cancer Society. Survival by stage of endometrial cancer [Internet]. Atlanta, GA: American Cancer Society; 2016 Feb 29 [cited 2016 Sep 10]. Available from: https://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-survival-rates.
  15. Turan T, Ureyen I, Duzguner I, Ozkaya E, Tasci T, Karalok A, et al. Analysis of patients with stage IIIC endometrial cancer. Int J Gynecol Cancer 2014;24:1033-41. https://doi.org/10.1097/IGC.0000000000000154
  16. Fujimoto T, Nanjyo H, Nakamura A, Yokoyama Y, Takano T, Shoji T, et al. Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer. Gynecol Oncol 2007;107:253-9. https://doi.org/10.1016/j.ygyno.2007.06.009
  17. Hatoum HA, Jamali FR, El-Saghir NS, Musallam KM, Seoud M, Dimassi H, et al. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Ann Surg Oncol 2009;16:3388-95. https://doi.org/10.1245/s10434-009-0653-8
  18. Rossi CR, Mocellin S, Pasquali S, Pilati P, Nitti D. N-ratio: a novel independent prognostic factor for patients with stage-III cutaneous melanoma. Ann Surg Oncol 2008;15:310-5. https://doi.org/10.1245/s10434-007-9641-z
  19. Zhang MR, Xie TH, Chi JL, Li Y, Yang L, Yu YY, et al. Prognostic role of the lymph node ratio in node positive colorectal cancer: a meta-analysis. Oncotarget 2016;7:72898-907.
  20. Greggi S, Franchi M, Aletti G, Biglia N, Ditto A, Fagotti A, et al. Management of endometrial cancer in Italy: a national survey endorsed by the Italian Society of Gynecologic Oncology. Int J Surg 2014;12:1038-44. https://doi.org/10.1016/j.ijsu.2014.08.356
  21. Rosen PP, Saigo PE, Braun DW, Weathers E, Fracchia AA, Kinne DW. Axillary micro- and macrometastases in breast cancer: prognostic significance of tumor size. Ann Surg 1981;194:585-91. https://doi.org/10.1097/00000658-198111000-00006
  22. SGO Clinical Practice Endometrial Cancer Working Group, Burke WM, Orr J, Leitao M, Salom E, Gehrig P, et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol 2014;134:385-92. https://doi.org/10.1016/j.ygyno.2014.05.018
  23. Touhami O, Trinh XB, Gregoire J, Sebastianelli A, Renaud MC, Grondin K, et al. Predictors of non-sentinel lymph node (non-SLN) metastasis in patients with sentinel lymph node (SLN) metastasis in endometrial cancer. Gynecol Oncol 2015;138:41-5. https://doi.org/10.1016/j.ygyno.2015.04.008
  24. St. Clair CM, Eriksson AG, Ducie JA, Jewell EL, Alektiar KM, Hensley ML, et al. Low-volume lymph node metastasis discovered during sentinel lymph node mapping for endometrial carcinoma. Ann Surg Oncol 2016;23:1653-9. https://doi.org/10.1245/s10434-015-5040-z
  25. Ducie JA, Eriksson AG, Ali N, McGree ME, Weaver AL, Bogani G, et al. Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease. Gynecol Oncol 2017;147:541-8. https://doi.org/10.1016/j.ygyno.2017.09.030
  26. Fleming ND, Soliman PT, Westin SN, dos Reis R, Munsell M, Klopp AH, et al. Impact of lymph node ratio and adjuvant therapy in node-positive endometrioid endometrial cancer. Int J Gynecol Cancer 2015;25:1437-44. https://doi.org/10.1097/IGC.0000000000000510
  27. Polterauer S, Khalil S, Zivanovic O, Abu-Rustum NR, Hofstetter G, Concin N, et al. Prognostic value of lymph node ratio and clinicopathologic parameters in patients diagnosed with stage IIIC endometrial cancer. Obstet Gynecol 2012;119:1210-8. https://doi.org/10.1097/AOG.0b013e318255060c

Cited by

  1. Intra-operative assessment of sentinel lymph node status by one-step nucleic acid amplification assay (OSNA) in early endometrial cancer: a prospective study vol.29, pp.6, 2018, https://doi.org/10.1136/ijgc-2018-000113
  2. Construction and validation of nomograms for predicting the prognosis of grade 3 endometrial endometrioid adenocarcinoma cancers: a SEER-based study vol.12, pp.1, 2018, https://doi.org/10.1080/21655979.2021.1922247
  3. Surgical treatment and fertility perservation in endometrial cancer vol.55, pp.2, 2018, https://doi.org/10.2478/raon-2021-0009